Sector Gamma AS Increases Stock Position in Baxter International Inc (NYSE:BAX)

Share on StockTwits

Sector Gamma AS increased its position in shares of Baxter International Inc (NYSE:BAX) by 2.2% during the 3rd quarter, Holdings Channel reports. The firm owned 472,305 shares of the medical instruments supplier’s stock after acquiring an additional 10,000 shares during the period. Baxter International comprises 7.0% of Sector Gamma AS’s investment portfolio, making the stock its 4th biggest position. Sector Gamma AS’s holdings in Baxter International were worth $41,313,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Pensionfund DSM Netherlands bought a new stake in Baxter International in the 2nd quarter valued at $2,948,000. Pensionfund Sabic bought a new stake in Baxter International in the 2nd quarter valued at $1,966,000. Beese Fulmer Investment Management Inc. increased its holdings in Baxter International by 0.3% in the 2nd quarter. Beese Fulmer Investment Management Inc. now owns 66,471 shares of the medical instruments supplier’s stock valued at $5,444,000 after acquiring an additional 193 shares during the last quarter. WINTON GROUP Ltd increased its holdings in Baxter International by 293.0% in the 2nd quarter. WINTON GROUP Ltd now owns 24,928 shares of the medical instruments supplier’s stock valued at $2,042,000 after acquiring an additional 18,585 shares during the last quarter. Finally, Carroll Financial Associates Inc. increased its holdings in Baxter International by 4.3% in the 2nd quarter. Carroll Financial Associates Inc. now owns 4,418 shares of the medical instruments supplier’s stock valued at $361,000 after acquiring an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 83.45% of the company’s stock.

In related news, Director James R. Gavin III sold 7,950 shares of Baxter International stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $87.63, for a total transaction of $696,658.50. Following the completion of the transaction, the director now directly owns 40,932 shares of the company’s stock, valued at approximately $3,586,871.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Andrew Frye sold 3,332 shares of Baxter International stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $88.00, for a total transaction of $293,216.00. Following the transaction, the senior vice president now directly owns 16,391 shares of the company’s stock, valued at $1,442,408. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,396 shares of company stock worth $1,528,575. Insiders own 0.70% of the company’s stock.

Shares of Baxter International stock traded up $0.51 during trading hours on Friday, reaching $78.51. The company’s stock had a trading volume of 3,017,392 shares, compared to its average volume of 2,768,937. The firm has a 50 day moving average price of $84.08 and a 200-day moving average price of $82.11. Baxter International Inc has a one year low of $61.40 and a one year high of $89.93. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The stock has a market cap of $39.56 billion, a P/E ratio of 25.74, a P/E/G ratio of 2.00 and a beta of 0.97.

A number of analysts have issued reports on the stock. Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a report on Tuesday, September 10th. Royal Bank of Canada set a $87.00 price target on shares of Baxter International and gave the company a “hold” rating in a report on Friday, July 26th. Raymond James lifted their price target on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 26th. BMO Capital Markets lifted their price target on shares of Baxter International to $95.00 and gave the company an “outperform” rating in a report on Friday, July 26th. Finally, JPMorgan Chase & Co. set a $94.00 price target on shares of Baxter International and gave the company a “buy” rating in a report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $90.14.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.